| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Physical and Rehabilitation Medicine | 2 | 2022 | 46 | 0.940 |
Why?
|
| Receptor, ErbB-2 | 15 | 2023 | 2518 | 0.830 |
Why?
|
| Breast Neoplasms | 31 | 2023 | 15694 | 0.830 |
Why?
|
| Lymphedema | 2 | 2023 | 239 | 0.720 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2019 | 11 | 0.690 |
Why?
|
| Phyllodes Tumor | 2 | 2013 | 62 | 0.550 |
Why?
|
| Trastuzumab | 10 | 2023 | 696 | 0.430 |
Why?
|
| Quinazolines | 11 | 2023 | 923 | 0.430 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 167 | 0.410 |
Why?
|
| Head and Neck Neoplasms | 3 | 2024 | 3976 | 0.390 |
Why?
|
| Ultrasonography, Mammary | 1 | 2013 | 380 | 0.380 |
Why?
|
| Receptors, Estrogen | 11 | 2022 | 2086 | 0.360 |
Why?
|
| Ki-67 Antigen | 3 | 2022 | 666 | 0.310 |
Why?
|
| Tamoxifen | 5 | 2016 | 876 | 0.290 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2016 | 840 | 0.290 |
Why?
|
| Osteosarcoma | 1 | 2013 | 929 | 0.280 |
Why?
|
| Neoadjuvant Therapy | 9 | 2023 | 4975 | 0.250 |
Why?
|
| STAT5 Transcription Factor | 2 | 2022 | 214 | 0.230 |
Why?
|
| Neoplasms | 5 | 2023 | 15193 | 0.210 |
Why?
|
| Human Trafficking | 1 | 2022 | 38 | 0.210 |
Why?
|
| Biomarkers, Tumor | 9 | 2023 | 10331 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2022 | 5178 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 15862 | 0.190 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2017 | 986 | 0.190 |
Why?
|
| Gene Editing | 1 | 2023 | 216 | 0.190 |
Why?
|
| Physical Therapy Modalities | 1 | 2021 | 95 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 6 | 2020 | 2330 | 0.190 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 521 | 0.180 |
Why?
|
| Genes, erbB-2 | 3 | 2011 | 229 | 0.180 |
Why?
|
| Deglutition Disorders | 1 | 2024 | 447 | 0.180 |
Why?
|
| Immunohistochemistry | 4 | 2022 | 7548 | 0.170 |
Why?
|
| Quinolines | 1 | 2022 | 383 | 0.170 |
Why?
|
| Female | 36 | 2023 | 141928 | 0.160 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 1 | 2018 | 32 | 0.160 |
Why?
|
| Pathology, Clinical | 1 | 2019 | 152 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2018 | 3821 | 0.160 |
Why?
|
| Optical Imaging | 1 | 2019 | 157 | 0.150 |
Why?
|
| Humans | 41 | 2024 | 261506 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 65 | 0.140 |
Why?
|
| Gene Expression | 3 | 2020 | 3570 | 0.130 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2014 | 342 | 0.130 |
Why?
|
| Estradiol | 2 | 2016 | 748 | 0.130 |
Why?
|
| Tissue Array Analysis | 2 | 2015 | 760 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2020 | 3251 | 0.130 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 246 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2019 | 1234 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 992 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2016 | 519 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 862 | 0.120 |
Why?
|
| Granulomatous Mastitis | 1 | 2013 | 9 | 0.120 |
Why?
|
| Hospitals, County | 1 | 2013 | 28 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2013 | 87 | 0.110 |
Why?
|
| Cell Line, Tumor | 8 | 2018 | 14551 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 4 | 2011 | 4367 | 0.110 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 593 | 0.110 |
Why?
|
| Fibroadenoma | 1 | 2012 | 25 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 701 | 0.100 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 222 | 0.100 |
Why?
|
| Atrioventricular Node | 1 | 2011 | 23 | 0.100 |
Why?
|
| Death, Sudden | 1 | 2011 | 59 | 0.100 |
Why?
|
| Disease Models, Animal | 4 | 2023 | 7222 | 0.100 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 4744 | 0.100 |
Why?
|
| Mice | 13 | 2023 | 34495 | 0.100 |
Why?
|
| Signal Transduction | 8 | 2018 | 11965 | 0.100 |
Why?
|
| Transcriptome | 2 | 2016 | 1859 | 0.100 |
Why?
|
| Middle Aged | 13 | 2020 | 86204 | 0.100 |
Why?
|
| Treatment Outcome | 8 | 2023 | 32848 | 0.090 |
Why?
|
| Quality of Life | 2 | 2024 | 4532 | 0.090 |
Why?
|
| Sirolimus | 1 | 2014 | 814 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 607 | 0.090 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 14289 | 0.090 |
Why?
|
| Adult | 14 | 2022 | 77950 | 0.090 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2009 | 132 | 0.090 |
Why?
|
| Oncogenes | 2 | 2013 | 673 | 0.090 |
Why?
|
| Animals | 15 | 2023 | 59536 | 0.090 |
Why?
|
| Mice, Nude | 5 | 2018 | 4307 | 0.080 |
Why?
|
| Heart Neoplasms | 1 | 2011 | 214 | 0.080 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2008 | 110 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2017 | 8873 | 0.080 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2018 | 1215 | 0.080 |
Why?
|
| Lymphoma, T-Cell | 1 | 2011 | 361 | 0.080 |
Why?
|
| Smad5 Protein | 1 | 2007 | 27 | 0.080 |
Why?
|
| Smad1 Protein | 1 | 2007 | 35 | 0.080 |
Why?
|
| Lentivirus | 1 | 2008 | 169 | 0.080 |
Why?
|
| Fibroblasts | 1 | 2014 | 1682 | 0.070 |
Why?
|
| Adnexa Uteri | 1 | 2006 | 15 | 0.070 |
Why?
|
| Jejunal Diseases | 1 | 2006 | 25 | 0.070 |
Why?
|
| Ovarian Diseases | 1 | 2006 | 54 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2022 | 2359 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2019 | 9244 | 0.070 |
Why?
|
| Antibodies, Blocking | 1 | 2006 | 91 | 0.070 |
Why?
|
| Fistula | 1 | 2006 | 76 | 0.070 |
Why?
|
| Exercise | 2 | 2024 | 1183 | 0.070 |
Why?
|
| Antigens, Differentiation | 1 | 2006 | 238 | 0.070 |
Why?
|
| CA-125 Antigen | 1 | 2006 | 226 | 0.070 |
Why?
|
| ErbB Receptors | 3 | 2011 | 2295 | 0.060 |
Why?
|
| Models, Biological | 1 | 2014 | 3254 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2009 | 1620 | 0.060 |
Why?
|
| MCF-7 Cells | 2 | 2016 | 550 | 0.060 |
Why?
|
| Ovary | 1 | 2007 | 668 | 0.060 |
Why?
|
| Mammary Glands, Animal | 2 | 2022 | 533 | 0.060 |
Why?
|
| Testis | 1 | 2007 | 717 | 0.060 |
Why?
|
| Tumor Microenvironment | 1 | 2014 | 2864 | 0.060 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 140 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2008 | 1694 | 0.060 |
Why?
|
| Recombinational DNA Repair | 1 | 2023 | 79 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 5112 | 0.050 |
Why?
|
| Pelvic Neoplasms | 1 | 2003 | 189 | 0.050 |
Why?
|
| Breast | 2 | 2022 | 1344 | 0.050 |
Why?
|
| Receptors, Progesterone | 3 | 2015 | 1392 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2024 | 288 | 0.050 |
Why?
|
| Biopsy | 2 | 2022 | 3443 | 0.050 |
Why?
|
| Cell Survival | 2 | 2018 | 3045 | 0.050 |
Why?
|
| CRISPR-Cas Systems | 1 | 2023 | 323 | 0.040 |
Why?
|
| Prognosis | 4 | 2020 | 21713 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 6009 | 0.040 |
Why?
|
| Aged | 8 | 2020 | 70117 | 0.040 |
Why?
|
| Mutation | 5 | 2018 | 15179 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 600 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 447 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 671 | 0.040 |
Why?
|
| Survivors | 1 | 2023 | 1031 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 665 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2020 | 9180 | 0.040 |
Why?
|
| Cell Division | 2 | 2013 | 2489 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 13658 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2013 | 2218 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 3101 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2022 | 1818 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2022 | 1648 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 860 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 29902 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 661 | 0.030 |
Why?
|
| HIV Infections | 1 | 2006 | 2134 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2017 | 7226 | 0.030 |
Why?
|
| Doxycycline | 1 | 2014 | 178 | 0.030 |
Why?
|
| Male | 4 | 2019 | 123000 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 3890 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 4757 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 1313 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 733 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 4844 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2014 | 639 | 0.030 |
Why?
|
| Forensic Pathology | 1 | 2011 | 9 | 0.030 |
Why?
|
| Steroids | 1 | 2013 | 356 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1077 | 0.020 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2012 | 134 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2013 | 5710 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 905 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 2216 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 5159 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 437 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2018 | 4804 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 116 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 580 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 4654 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2008 | 5637 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2013 | 1869 | 0.020 |
Why?
|
| Melanoma | 1 | 2006 | 5317 | 0.020 |
Why?
|
| Keratin-9 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Alpharetrovirus | 1 | 2008 | 7 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 1493 | 0.020 |
Why?
|
| Triazoles | 1 | 2013 | 617 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 12926 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 906 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2008 | 138 | 0.020 |
Why?
|
| Smad8 Protein | 1 | 2007 | 9 | 0.020 |
Why?
|
| Sertoli Cell Tumor | 1 | 2007 | 12 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2008 | 260 | 0.020 |
Why?
|
| Apoptosis | 2 | 2013 | 7591 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 1678 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 1546 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 1519 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2013 | 1026 | 0.020 |
Why?
|
| Granulosa Cell Tumor | 1 | 2007 | 77 | 0.020 |
Why?
|
| Mammography | 1 | 2013 | 1010 | 0.020 |
Why?
|
| HIV | 1 | 2008 | 229 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2054 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 3472 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 2450 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 1863 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 1529 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 598 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2006 | 119 | 0.020 |
Why?
|
| Ascites | 1 | 2006 | 198 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 423 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2006 | 330 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 669 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 4758 | 0.020 |
Why?
|
| Fertility | 1 | 2007 | 336 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 1082 | 0.020 |
Why?
|
| Myocardium | 1 | 2011 | 1313 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 14889 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2006 | 305 | 0.020 |
Why?
|
| Obesity, Morbid | 1 | 2006 | 224 | 0.010 |
Why?
|
| Biomarkers | 1 | 2015 | 5047 | 0.010 |
Why?
|
| Testicular Neoplasms | 1 | 2007 | 529 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2006 | 478 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 4892 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 3981 | 0.010 |
Why?
|
| Estrogens | 1 | 2007 | 751 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2006 | 842 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2007 | 1442 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 2006 | 657 | 0.010 |
Why?
|
| Disease Progression | 1 | 2013 | 6682 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 6295 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2008 | 3033 | 0.010 |
Why?
|
| Child | 1 | 2022 | 29154 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2006 | 1385 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 4988 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 21445 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 7573 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2992 | 0.010 |
Why?
|
| Research Design | 1 | 2008 | 1544 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 4143 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2013 | 37905 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2003 | 825 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6207 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 11538 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 10001 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 6869 | 0.010 |
Why?
|
| Survival Rate | 1 | 2009 | 12221 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 2576 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2006 | 3869 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 17523 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 7551 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 10035 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 4557 | 0.010 |
Why?
|